Rune Labs, a neurology software and data platform provider, has recently announced a collaboration with biopharmaceutical firm BlueRock Therapeutics, a wholly owned subsidiary of Bayer AG. BlueRock will use the clinical trial technology of Rune Labs featuring patient monitoring and data collection facilities, named StriveStudy, to delve into the root cause of the Parkinson’s disease.

This is the first partnership of both companies with each other and is also the first deployment of the StriveStudy clinical trial platform, in order to facilitate better research of therapeutics to treat movement disorders. Rune Labs’ technology will be used by BlueRock in a non-interventional study to capture Parkinson’s symptoms data through Apple Watch-enabled tools for data collection and remote patient monitoring.

The CEO of Rune Labs, Brian Pepin, has shared that the research on Parkinson’s disease has been limited in the past, since people who suffer from the disorder display varying sets of symptoms. Furthermore, subjective tools commonly used by researchers, such as patient-reported questionnaires, are unable to capture the dynamic nature of the disease, he added. Through this collaboration, claims Pepin, the companies will work on establishing a baseline dataset for symptoms of Parkinson’s disease to fully derive benefits from advanced therapies and increase the efficiency of future clinical trials.

According to President and CEO of BlueRock Therapeutics, Seth Ettenberg, the firm is looking forward to partnering with Rune Labs to drive progress in the development of medical therapy for diseases such as Parkinson’s.

Rune Labs is also providing a first-hand chance to conduct trials for and streamline BlueRock’s stem cell-based therapy bemdaneprocel technology. Through StriveStudy, BlueRock will be able to conduct subsequent data analysis on baseline and follow-up data, including dyskinesias, to gain a more comprehensive understanding of the therapeutic advantages of the first-in-class therapy.

For the record, RuneLabs is a data analytics company that is involved in precision neurology therapy development.  The firm has financial help from various investors like Eclipse Ventures, DigiTx, and Moment Ventures, among others.

Source Credit: https://www.prnewswire.com/news-releases/bluerock-therapeutics-to-use-rune-labs-clinical-trial-platform-to-better-characterize-parkinsons-disease-state-in-cell-therapy-trials-301771114.html